JPRN-jRCT2021190013进行中（未招募）2 期
Phase IIa study (doctor-led trial) for the efficacy and safety of SJP-0008 in central retinal artery occlusion
akazawa Toru0 个研究点目标入组 20 人开始时间: 2019年12月11日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •(1) Age 20 years or older at the time consent was obtained
- •(2) Written consent for joining the sutudy was available
- •(3) The onset of nonarteritic retinal artery occlusion (central retinal artery occlusion) occurred expected to start study drug administration within 3 to 48 hours before joining the study
- •(4) Decimal visual acuity in the included eye better than hand motion and worse than 0.1 in a screening test
- •(5)All of the following in the screening test before the study
- •Hemoglobin amount >= 10 g / dL
- •White blood cell count>= 2,000 / uL
- •Platelet count >=100,000 / uL
- •AST =< 50 IU / L
- •ALT =< 50 IU / L
- •Total bilirubin =< 1.5 mg / dL
- •Creatinine =< 1.5 mg / dL
- •Calcium >=7.5mg / dL, =< 10.5mg / d
排除标准
- •(1) Presence of vision-affecting disease in the included eye at risk of progression during the trial, including diabetic retinopathy, retinal detachment, macular disease, or retinitis pigmentosa. However, such patients were included if the primary or other physician deemed inclusion unlikely to affect the safety of the patient.
- •(2) History of internal eye surgery (including laser treatment) within 90 days before enrollment
- •(3) Patients with less than 0.1 visual acuity
- •(4) From the time of obtaining consent to the end of the study drug administration period, patients who are not willing to perform appropriate contraception using effective contraceptive methods (eg condoms, intrauterine devices, oral contraceptives), pregnant women or lactating women
- •(5) Patients undergoing unapproved or off-label treatment in other clinical trials within 4 weeks before the time consent was obtained
- •(6)Patients who received the study drug in the past
- •(7) Patients with poor control of co-morbidity
- •(8) A judgement that inclusion was inappropriate by the primary or other physician for any other reason
研究者
相似试验
尚未招募
不适用
Phase Ib/II Clinical Trial to Evaluate the efficacy and safety of Neo-adjuvant chemotherapy with Autologous Cytokine-Induced Killer Cells Therapy in patients with estrogen receptor negative/HER-2 negative breast cancerKCT0008408ational Cancer Center51
进行中（未招募）
1 期
Study to evaluate the efficacy of FOLFIRI + aflibercept in patients with metastatic colorectal cancer previously treated with oxaliplatin with or without ACE polymorphismsMetastatic colorectal cancerMedDRA version: 19.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2016-001508-45-ESGrupo de Tratamiento de los Tumores Digestivos (TTD)100
进行中（未招募）
1 期
Phase II clinical trial evaluating the efficacy of PF-05212384 (PKI-587) for patients with myeloid neoplasm secondary to chemo-radiotherapy (t-AML/MDS) or de novo relapsed or refractory AMMyeloid neoplasm secondary to chemo-radiotherapy (t-AML/MDS) /or relapsed or refractory de novo AML /or de novo AML at diagnostic considered unfit to benefit from induction therapy with chemotherapy associated aplasiaMedDRA version: 17.1Level: LLTClassification code 10066572Term: AML progressionSystem Organ Class: 100000004864EUCTR2014-002752-50-FRINSTITUT CURIE
进行中（未招募）
1 期
MK-5172 + MK-8742 in HCV-infected subjects with hepatic insufficiency (CP-B)MedDRA version: 18.0Level: LLTClassification code 10019751Term: Hepatitis C virusSystem Organ Class: 100000004848Hepatitis CEUCTR2014-000672-25-ITMERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.6
招募中
不适用
Phase II clinical trial for the effectiveness and safety of AW-PD01 (helium / oxygen mixed gas) for respiratory failure in children and infants with airway stenotic lesions: Single facility single group open label intervention studyRespiratory failure, BronchiolitisJPRN-UMIN000025065Tokyo Metropolitan Children's Medical Center10